中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins

文献类型：期刊论文

作者Liu, Xiaoyun1,2; Feng, Dan1,3; Zheng, Mingyue1,2; Cui, Yongmei3; Zhong, Dafang1,2
刊名DRUG METABOLISM AND PHARMACOKINETICS
出版日期2020-10-01
卷号35期号:5页码:456-465
ISSN号1347-4367
关键词Covalent tyrosine kinase inhibitors Covalent binding Human serum albumin Molecular docking Quantitative calculations Linear modeling Species difference
DOI10.1016/j.dmpk.2020.07.002
通讯作者Zhong, Dafang(dfzhong@simm.ac.cn)
英文摘要Eight covalent tyrosine kinase inhibitors (TKIs) were investigated to determine the characteristics of their covalent binding to plasma proteins. The data revealed that their covalent binding to plasma proteins is of species difference. In addition to the reports on neratinib and pyrotinib, osimertinib, alflutinib, AST5902, and ibrutinib were confirmed to covalently bind to the Lys-190 of human serum albumin (HSA). Molecular docking was used to simulate the binding mode of TKIs to HSA. The results exhibited the non-covalent interactions between covalent TKIs and HSA, which stabilize the TKIs-HSA complex and explain the selectivity of covalent binding. The t(1/2) values of TKIs that are covalently bound to HSA or human plasma proteins were studied in vitro, and the features highly correlated with the t(1/2) were determined by quantitative calculations and linear modeling. Reversibility of the covalent binding and the factors affecting the process of reversibility were evaluated. In conclusion, acrylamide moiety of covalent TKIs can covalently bind to lysine residue of HSA, most of which were determined to be Lys-190. The covalent binding is of species difference, especially between animal and human. Except for osimertinib, covalent binding between TKIs and HSA are reversible. (C) 2020 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.
资助项目National Natural Science Foundation of China[81521005] ; Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12050306]
WOS研究方向Pharmacology & Pharmacy
语种英语
出版者JAPANESE SOC STUDY XENOBIOTICS
WOS记录号WOS:000575073000007
源URL[http://119.78.100.183/handle/2S10ELR8/291329]  
专题新药研究国家重点实验室
通讯作者Zhong, Dafang
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
3.Shanghai Univ, Dept Chem, Shanghai 200444, Peoples R China
推荐引用方式
GB/T 7714		 Liu, Xiaoyun,Feng, Dan,Zheng, Mingyue,et al. Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins[J]. DRUG METABOLISM AND PHARMACOKINETICS,2020,35(5):456-465.
APA Liu, Xiaoyun,Feng, Dan,Zheng, Mingyue,Cui, Yongmei,&Zhong, Dafang.(2020).Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins.DRUG METABOLISM AND PHARMACOKINETICS,35(5),456-465.
MLA Liu, Xiaoyun,et al."Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins".DRUG METABOLISM AND PHARMACOKINETICS 35.5(2020):456-465.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。